Maia Bernardo, Kasuki Leandro, Gadelha Mônica R
Neuroendocrinology Research Center/Endocrinology Division - Medical School and Hospital Universitário Clementino Fraga Filho - Universidade Federal do Rio de Janeiro, Rio de Janeiro, Brazil.
Neuroendocrinology Division - Instituto Estadual do Cérebro Paulo Niemeyer, Rio de Janeiro, Brazil.
Endocr Connect. 2020 Dec;9(12):R274-R285. doi: 10.1530/EC-20-0433.
Acromegaly is a systemic disease associated with increased morbidity and mortality. Most of these comorbidities can be prevented or delayed with adequate disease treatment. Although three modalities of treatment (surgery, medical treatment, and radiotherapy) are available and new drugs were approved in the last decades, there are still some patients that maintain disease activity despite treatment. Therefore, there is a need for novel therapies for acromegaly and for that purpose new formulations of currently used drugs and also new drugs are currently under study. In this review, we summarize the novel therapies for acromegaly.
肢端肥大症是一种与发病率和死亡率增加相关的全身性疾病。通过适当的疾病治疗,这些合并症大多可以预防或延缓。尽管有三种治疗方式(手术、药物治疗和放射治疗)可用,并且在过去几十年中有新药获批,但仍有一些患者尽管接受了治疗,疾病仍处于活动状态。因此,需要针对肢端肥大症的新型疗法,为此目前正在研究现有药物的新剂型以及新药。在本综述中,我们总结了肢端肥大症的新型疗法。